Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest InnerCool Therapies Inc. Stories

2013-08-14 08:30:49

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the second quarter ended June 30, 2013, and reported on recent highlights and other business developments including: -- Distribution agreement with AvKARE Inc. for the sale and distribution of Excellagen into government medical facilities throughout the United States. AvKARE services a diverse customer base that includes government (federal,...

2010-01-04 16:57:00

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the company's current listing exchange indicating that the company is currently considered to be noncompliant with certain listing requirements of the NYSE AMEX LLC. Based on the company's quarterly report on Form 10-Q, which was filed on November 9, 2009, noncompliance was noted with respect to the requirements for minimum stockholders' equity under...

2009-07-24 08:00:00

SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has completed the asset sale of Cardium's InnerCool Therapies business ("InnerCool") to Royal Philips Electronics (NYSE: PHG, AEX: PHI). The asset purchase transaction was for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) About Royal Philips Electronics Royal...

2009-07-15 07:05:00

AMSTERDAM and SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Royal Philips (AEX: PHI, NYSE: PHG) announced today that it has reached an agreement to acquire the assets of InnerCool Therapies Inc., a pioneer in the field of therapeutic hypothermia, which involves the management of a patient's body temperature. InnerCool, a wholly-owned subsidiary of Cardium Therapeutics, Inc. (NYSE Amex: CXM), will be acquired in an asset purchase transaction for US $11.25M, as well as the transfer of...

2009-07-15 07:00:00

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has entered into a definitive Asset Purchase Agreement for the acquisition of Cardium's InnerCool Therapies business ("InnerCool") by Royal Philips Electronics (NYSE: PHG, AEX: PHI). The asset purchase transaction for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables, is subject to customary closing conditions but is expected to...

2009-06-17 08:00:00

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced it is scheduled to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009 according to a preliminary list of additions posted on www.russell.com. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S....

2009-05-28 08:00:00

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced a presentation entitled "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers" at the Late Stage Industry Clinical Trials Symposium at the American Society of Gene Therapy (ASGT) Annual meeting in San Diego, California, on May 27, 2009. Dr. Barbara K. Sosnowski, Cardium's Vice President of Biologics Development and the...

2009-05-12 08:15:00

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the...

2009-05-11 16:33:00

SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its first quarter ended March 31, 2009, and on recent developments and future outlook. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) Cardium made significant progress in the first quarter 2009 as the Company continued to focus its efforts on the InnerCool Therapies and Tissue Repair Company subsidiaries, both of which we believe are advancing toward...

2009-05-07 08:00:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced significant new formulation enhancements for its Excellarate(TM) product candidate that are designed to simplify and broaden the use of Excellarate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and...